For research use only. Not for therapeutic Use.
hMAO-B-IN-4 (compound B10) is a selective, reversible and blood–brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC50 value and a Ki value of 0.067 and 0.03 μM, respectively. hMAO-B-IN-4 inhibits hMAO-A with an IC50 value of 33.82 μM. hMAO-B-IN-4 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research[1].
hMAO-B-IN-4 (0-40 μM) shows high selectivity to hMAO-B than hMAO-A with a SI value of 504.791[1].
hMAO-B-IN-4 (0-40 μM) inhibits hMAO-A and hMAO-B with IC50 values of 33.821 and 0.067 μM, respectively[1].
| Catalog Number | I041952 |
| CAS Number | 1666119-75-0 |
| Synonyms | (E)-3-(4-phenylmethoxyphenyl)-1-thiophen-2-ylprop-2-en-1-one |
| Molecular Formula | C20H16O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C20H16O2S/c21-19(20-7-4-14-23-20)13-10-16-8-11-18(12-9-16)22-15-17-5-2-1-3-6-17/h1-14H,15H2/b13-10+ |
| InChIKey | MKSMRBDQELHEBO-JLHYYAGUSA-N |
| SMILES | C1=CC=C(C=C1)COC2=CC=C(C=C2)C=CC(=O)C3=CC=CS3 |
| Reference | [1]. Sudevan ST, et al. Introduction of benzyloxy pharmacophore into aryl/heteroaryl chalcone motifs as a new class of monoamine oxidase B inhibitors. Sci Rep. 2022 Dec 27;12(1):22404. |
